Chimerix Inc (CMRX.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|78||2013||Independent Chairman of the Board|
|48||2014||President, Chief Executive Officer, Chief Medical Officer, Director|
|56||2012||Chief Financial Officer, Senior Vice President, Corporate Secretary|
|2017||Chief Manufacturing and Technology Officer|
|2017||Vice President - Regulatory Affairs|
- UPDATE 1-FDA OKs Merck drug that prevents infection post-stem cell transplant
- BRIEF-Chimerix reports Q3 loss of $0.37/shr
- BRIEF-Chimerix Inc files for mixed shelf of up to $250 million
- BRIEF-Chimerix Inc entered into agreement with Cowen and Co
- BRIEF-Chimerix Inc appoints Heather Knight-Trent vice president of regulatory affairs